Abstract
Improving the means of drug delivery has become an important field of pharmaceutical research. The development of safe and advanced vectors for gene therapy and other novel therapies will allow for targeted delivery of pharmaceutically active agents and carries promise to improve therapies both through increased efficiency (e.g. improved cellular uptake of the active drug) as well as lower toxicity (e.g. through targeted delivery only to the cells requiring treatment) for a large number of pharmaceutical agents. Here we are reviewing the nascent field using live bacteria as vectors for therapeutic and preventive agents in a wide range of areas, from vaccine purposes to gene therapy and delivery of therapeutic RNA interference. This review focuses particularly on the use of E. coli derived strains for therapeutic delivery.
Keywords: Bacterial delivery, invasin, listeriolysin, attenuation, FDA, gene transfer, RNAi, transkingdom RNAi, tkRNAi, dapA
Current Gene Therapy
Title: Engineered E. coli as Vehicles for Targeted Therapeutics
Volume: 10 Issue: 1
Author(s): Caitlin Buttaro and Johannes H. Fruehauf
Affiliation:
Keywords: Bacterial delivery, invasin, listeriolysin, attenuation, FDA, gene transfer, RNAi, transkingdom RNAi, tkRNAi, dapA
Abstract: Improving the means of drug delivery has become an important field of pharmaceutical research. The development of safe and advanced vectors for gene therapy and other novel therapies will allow for targeted delivery of pharmaceutically active agents and carries promise to improve therapies both through increased efficiency (e.g. improved cellular uptake of the active drug) as well as lower toxicity (e.g. through targeted delivery only to the cells requiring treatment) for a large number of pharmaceutical agents. Here we are reviewing the nascent field using live bacteria as vectors for therapeutic and preventive agents in a wide range of areas, from vaccine purposes to gene therapy and delivery of therapeutic RNA interference. This review focuses particularly on the use of E. coli derived strains for therapeutic delivery.
Export Options
About this article
Cite this article as:
Buttaro Caitlin and Fruehauf H. Johannes, Engineered E. coli as Vehicles for Targeted Therapeutics, Current Gene Therapy 2010; 10 (1) . https://dx.doi.org/10.2174/156652310790945593
DOI https://dx.doi.org/10.2174/156652310790945593 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Mini-Reviews in Medicinal Chemistry A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets <i>In-silico</i> Studies and Wet-Lab Validation of Camptothecin Derivatives for Anti-Cancer Activity Against Liver (HepG2) and Lung (A549) Cancer Cell Lines
Current Topics in Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Review of the Biological Activity of Maslinic Acid
Current Drug Targets A Short Course on Virology / Vectorology / Gene Therapy
Current Gene Therapy Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma
Current Gene Therapy Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening